Market Overview:
The global herpes simplex virus treatment market reached a value of US$ 2.32 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.25 Billion by 2027 exhibiting a CAGR of 5.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Herpes simplex virus (HSV) is a contagious infection that can spread through saliva, semen, and vaginal secretions and cause painful blisters or ulcers. It is generally diagnosed through physical examinations, fluid sampling, and blood tests. At present, antiviral medications, such as famciclovir, acyclovir, and valacyclovir, are the most effective treatment options available for patients. These medications can be administered through oral or intravenous (IV) routes to help relieve symptoms, reduce the frequency and severity of outbreaks, and prevent the transmission of the virus.
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Herpes Simplex Virus Treatment Market Trends:
HSV increases the risk of acquiring and transmitting human immunodeficiency virus (HIV) infection and can also lead to serious complications like encephalitis and keratitis in people with long-term or chronic illnesses. This, in confluence with the growing percentage of people with chronic diseases, represents one of the significant factors driving the need for HSV treatment across the globe. Moreover, neonatal herpes is a serious condition that can occur when an infant is exposed to HSV in the genital tract during delivery. As neonatal herpes can cause lasting neurologic disability or death in infants, the rising birth rates are influencing the market positively. Apart from this, as reactivation of HSV infection generally occurs during the initial months of bone marrow and solid-organ transplants, the increasing number of people undergoing organ transplantation is contributing to the market growth. In line with this, researchers are focusing on developing new antiviral medications to expand the treatment options for orolabial and genital herpes. In addition, they are introducing antiviral cream or ointment that can relieve burning, itching, or tingling sensations of HSV, improve the quality of life of patients, and prevent infected people from spreading the virus.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global herpes simplex virus treatment market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, drug type, route of administration and distribution channel.
Breakup by Type:
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Herpes Simples Virus-1 Infection
- Herpes Simplex Virus-2 Infection
- Others
Breakup by Drug Type:
- Acyclovir
- Valacyclovir
- Famciclovir
- Others
Breakup by Route of Administration:
Breakup by Distribution Channel:
- Hospital Pharmacy
- Drug Stores
- Retail Stores
- Online Pharmacy
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agenus Inc., Apotex Inc., Avet Pharmaceuticals Inc., Carlsbad Tech, EPI Health LLC, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd. and Viatris Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Billion |
Segment Coverage |
Type, Drug Type, Route of Administration, Distribution Channel, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Agenus Inc., Apotex Inc., Avet Pharmaceuticals Inc., Carlsbad Tech, EPI Health LLC, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd. and Viatris Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global herpes simplex virus treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global herpes simplex virus treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global herpes simplex virus treatment market and who are the key players?
- What is the degree of competition in the industry?